TL;DR: The 15mg tesamorelin + ipamorelin vial is a fixed 2:1 blend — 10mg tesamorelin and 5mg ipamorelin freeze-dried together — so every draw carries both in that locked proportion. Reconstituted with 2mL bacteriostatic water you get 7.5mg/mL total: 50mcg tesamorelin and 25mcg ipamorelin per U-100 unit. A 1.4mg tesamorelin-equivalent draw is 28 units and rides along with 700mcg of ipamorelin, whether you wanted that or not. The blend calculator splits any draw into its components for you; this walks the arithmetic behind it.
What is actually in the vial
A pre-mixed vial is not two peptides sitting side by side. It is one lyophilised cake with both components dissolved into it at a ratio set at manufacture. For the common 15mg presentation:
| Component | Mass | Class | Receptor |
|---|---|---|---|
| Tesamorelin | 10mg | Stabilised GHRH(1-44) analog | GHRH receptor |
| Ipamorelin | 5mg | Pentapeptide secretagogue | GHS-R1a (ghrelin receptor) |
| Total | 15mg | 2:1 by mass |
Both peptides go into solution together and come out of the vial together. There is no draw volume, no reconstitution trick, and no injection schedule that changes the 2:1 relationship inside a single pull. That single fact is what makes the maths on this vial different from the maths on a single-compound vial, and it is the thing most people searching tesamorelin ipamorelin blend dosierung are actually trying to resolve. The vial reference page is tesamorelin + ipamorelin blend 15mg.
Concentration: three numbers, not one
Reconstitution works exactly as it does for any lyophilised peptide — mg/mL = mass ÷ mL of bacteriostatic water — but you run it three times: once for the total, once per component.
With 2mL of BAC water:
The conversion to syringe units is the standard one: on a U-100 barrel, 1mL = 100 units, so mcg per unit = (mg/mL × 1000) ÷ 100.
- Total: 7.5 × 1000 ÷ 100 = 75 mcg per unit
- Tesamorelin: 5.0 × 1000 ÷ 100 = 50 mcg per unit
- Ipamorelin: 2.5 × 1000 ÷ 100 = 25 mcg per unit
Those three numbers sum correctly (50 + 25 = 75), which is the sanity check worth doing every time you re-reconstitute. Run your own vial and water volume through the blend calculator rather than doing it longhand; the general method for any multi-component vial is in peptide blend dosing math.
What a tesamorelin-target draw delivers
Most researchers approach this vial with a tesamorelin figure in mind, because tesamorelin is the component with an approved label to anchor against — 2mg daily in the original Egrifta presentation, 1.4mg daily in Egrifta SV. So the practical question is: if I draw for tesamorelin, what am I getting in ipamorelin?
At 2mL reconstitution (50mcg tesamorelin per unit):
| Tesamorelin target | Units | Volume | Ipamorelin delivered | Blend total |
|---|---|---|---|---|
| 500mcg | 10 | 0.10mL | 250mcg | 750mcg |
| 1mg | 20 | 0.20mL | 500mcg | 1.5mg |
| 1.4mg | 28 | 0.28mL | 700mcg | 2.1mg |
| 2mg | 40 | 0.40mL | 1000mcg | 3mg |
Worked out longhand for the 1.4mg row: 1400 ÷ 50 = 28 units; 28 × 25 = 700mcg ipamorelin; 28 units = 0.28mL; 28 × 75 = 2100mcg total. Nothing exotic — just the same division done twice.
Fixed 2:1 blend, 15mg vial in 2mL BAC water. The ipamorelin column is not a choice — it is whatever the tesamorelin column forces.
For context: standalone ipamorelin research protocols commonly sit in the 100-300mcg per-administration band. A label-equivalent 2mg tesamorelin draw from this vial carries 1000mcg of ipamorelin — several times that range. Whether that matters depends entirely on what you are measuring, but it is worth naming rather than discovering later.
Running it the other way
Aim at the ipamorelin arm and the tesamorelin dose collapses:
| Ipamorelin target | Units | Volume | Tesamorelin delivered | Blend total |
|---|---|---|---|---|
| 100mcg | 4 | 0.04mL | 200mcg | 300mcg |
| 200mcg | 8 | 0.08mL | 400mcg | 600mcg |
| 300mcg | 12 | 0.12mL | 600mcg | 900mcg |
A 300mcg ipamorelin draw gives 600mcg tesamorelin — under half the 1.4mg Egrifta SV figure and under a third of the original 2mg one. There is no volume on the barrel that simultaneously delivers a label-range tesamorelin dose and a conventional ipamorelin dose. To get 1.4mg tesamorelin alongside 200mcg ipamorelin you would need a 7:1 vial. This one is 2:1, so it hands you 3.5× the ipamorelin at that tesamorelin target.
That is the entire trade-off of a fixed ratio stated as a number, and it is the thing to weigh before choosing a pre-mix over two vials.
Blend versus two separate vials
Same peptides, same mass, different degrees of freedom. Run a month at 1.4mg tesamorelin daily and compare:
Pre-mixed 15mg blend. 2.1mg per day (28 units) → 15 ÷ 2.1 ≈ 7 doses per vial. Thirty days needs roughly 4.3 vials, consuming about 42mg tesamorelin and 21mg ipamorelin. One injection, one reconstitution, one thing to store.
Separate vials. A tesamorelin 10mg vial in 2mL gives 5mg/mL — 28 units for 1.4mg, identical to the blend’s tesamorelin arm, so the tesamorelin calculator numbers carry straight across. An ipamorelin 5mg vial in 2mL gives 2.5mg/mL, so 200mcg is 8 units. Thirty days: ~4.3 tesamorelin vials plus 6mg of ipamorelin — about 1.2 ipamorelin vials.
The blend buys convenience and costs control. The separate-vial route costs a second reconstitution and either a second injection or a shared-syringe draw (28 units of one, then 8 of the other, into the same barrel), and buys you the ability to move either arm without touching the other. That comparison, including cost and stability angles, is expanded in premixed blends vs separate vials.
Two things the mass ratio hides
Molar ratio inverts it. Tesamorelin has a molecular weight of about 5136 g/mol; ipamorelin, a pentapeptide, is about 712 g/mol. So 10mg of tesamorelin is ~1.95 µmol while 5mg of ipamorelin is ~7.02 µmol. By mass the vial reads 2:1 tesamorelin-dominant; by molecules it is roughly 3.6:1 ipamorelin-dominant. Receptors count molecules, not milligrams. If you are reasoning about relative receptor occupancy rather than relative mass, the mass label points the wrong way.
Exposure ratio is not the vial ratio. Tesamorelin’s mean elimination half-life is around 8 minutes in healthy subjects after a single 1.4mg subcutaneous dose, with absolute subcutaneous bioavailability under 4%. Ipamorelin’s terminal half-life in healthy volunteers came in near 2 hours in the Gobburu PK/PD work. Both go in at once in a fixed 2:1 mass ratio; the GHRH signal is essentially gone while the secretagogue is still circulating. The vial ratio describes the syringe, not the time course.
Titrating a fixed-ratio vial
You cannot titrate one component. You can only slide the whole draw up and down the barrel, and both arms move together in lockstep. A representative research ladder on the 2mL reconstitution:
| Step | Units | Tesamorelin | Ipamorelin | Blend total |
|---|---|---|---|---|
| Start | 10 | 500mcg | 250mcg | 750mcg |
| Step 2 | 20 | 1mg | 500mcg | 1.5mg |
| Step 3 | 28 | 1.4mg | 700mcg | 2.1mg |
| Ceiling | 40 | 2mg | 1mg | 3mg |
Every row is just the unit count multiplied by 50 and by 25. If a protocol needs to hold tesamorelin steady while reducing ipamorelin — a common reason people go looking for dosaggio blend tesamorelina ipamorelina in the first place — the blend cannot do it, and the answer is two vials. If the protocol simply scales both, the blend is the cleaner instrument: one draw, one injection, no ratio drift from sloppy co-drawing.
One practical note on sourcing: for a blend, ask whether the certificate of analysis reports each component separately or only a combined purity figure. A single number cannot confirm that the 2:1 ratio in the powder matches the ratio on the label, and every calculation above assumes it does.
Frequently Asked Questions
How many units is a 2mg tesamorelin dose from the 15mg blend?
Forty units on a U-100 syringe, if you reconstituted with 2mL of bacteriostatic water. That gives 5mg/mL of tesamorelin, so 50mcg per unit, and 2000 ÷ 50 = 40 units. The same draw delivers 1000mcg of ipamorelin and 3mg of blend in total.
Can I dose tesamorelin and ipamorelin separately from a blend vial?
No. Both peptides are dissolved in the same solution, so any volume you draw contains them at the manufactured 2:1 ratio. Changing the bacteriostatic water volume changes the unit count but not the split. Independent titration requires two separate vials, reconstituted and drawn individually.
What does 1.4mg of tesamorelin give me in ipamorelin?
700mcg. At 2mL reconstitution, 1.4mg of tesamorelin is 28 units, and each unit carries 25mcg of ipamorelin, so 28 × 25 = 700mcg. That is above the 100-300mcg band typical of standalone ipamorelin protocols — the price of anchoring the draw to the tesamorelin label figure.
Does adding more bacteriostatic water change the blend ratio?
It does not. More water lowers the concentration of both components by the same factor, so a given dose simply lands on a higher unit mark. Use 3mL if you want finer resolution on small draws, 1mL if you want fewer, larger units. The 2:1 split is fixed in the powder.
Is the 15mg blend cheaper than buying two vials?
Per milligram, usually. Per protocol, often not — a 1.4mg tesamorelin target burns roughly 21mg of ipamorelin a month through the blend versus about 6mg through separate vials at 200mcg daily. Compare on ipamorelin consumed, not on sticker price. The tesamorelin calculator helps line the two routes up.
How long does a reconstituted 15mg blend vial last?
At 28 units daily you get 7 doses from a 2mL reconstitution, which sits comfortably inside the 3-4 week refrigerated window for a reconstituted peptide solution. At 10 units daily you get 20 doses — still inside it, but closer to the edge, so date the vial when you mix it.
References
- Falutz J, Allas S, Blot K, et al. “Metabolic effects of a growth hormone-releasing factor in patients with HIV.” New England Journal of Medicine, 2007;357(23):2359-2370. doi:10.1056/NEJMoa072375. (Tesamorelin 2mg daily vs placebo, 26 weeks; visceral adipose tissue -15.2% vs +5.0%, IGF-1 +81.0%.)
- EGRIFTA SV (tesamorelin for injection) prescribing information, Theratechnologies Inc. — DailyMed. (1.4mg daily dose; mean elimination half-life ~8 minutes in healthy subjects; absolute subcutaneous bioavailability under 4%.)
- Raun K, Hansen BS, Johansen NL, et al. “Ipamorelin, the first selective growth hormone secretagogue.” European Journal of Endocrinology, 1998;139(5):552-561. PMID: 9849822.
- Gobburu JV, Agersø H, Jusko WJ, Ynddal L. “Pharmacokinetic-pharmacodynamic modeling of ipamorelin, a growth hormone releasing peptide, in human volunteers.” Pharmaceutical Research, 1999;16(9):1412-1416. doi:10.1023/A:1018955126402. (Terminal half-life ~2 h; clearance 0.078 L/h/kg.)
- Bowers CY, Reynolds GA, Durham D, et al. “Growth hormone (GH)-releasing peptide stimulates GH release in normal men and acts synergistically with GH-releasing hormone.” Journal of Clinical Endocrinology & Metabolism, 1990;70(4):975-982.
- Stanley TL, Fourman LT, Feldpausch MN, et al. “Effects of tesamorelin on non-alcoholic fatty liver disease in HIV: a randomised, double-blind, multicentre trial.” The Lancet HIV, 2019;6(12):e821-e830.
This article is a research and educational reference only; the tesamorelin + ipamorelin blend is not an approved medicine, this is not medical advice, and it is not for human consumption.